Findings showed treatment with tolebrutinib did not significantly delay disability progression compared with placebo. A phase 3 study evaluating tolebrutinib for the treatment of primary progressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback